proteomic aging clocks

Proteomic aging clocks — blood-based protein signatures used to estimate biological age — are moving into clinical trials for the first time, raising questions about how regulators, including the US FDA, will evaluate them. Industry commentary is urging trial sponsors to understand validation requirements, biomarker standards and regulatory expectations now, before formal FDA guidance on aging biomarkers exists.